JP7428404B2 - Gsx1を使用した脊髄損傷(sci)および脳損傷の処置 - Google Patents

Gsx1を使用した脊髄損傷(sci)および脳損傷の処置 Download PDF

Info

Publication number
JP7428404B2
JP7428404B2 JP2021509976A JP2021509976A JP7428404B2 JP 7428404 B2 JP7428404 B2 JP 7428404B2 JP 2021509976 A JP2021509976 A JP 2021509976A JP 2021509976 A JP2021509976 A JP 2021509976A JP 7428404 B2 JP7428404 B2 JP 7428404B2
Authority
JP
Japan
Prior art keywords
gsx1
protein
nucleic acid
seq
cpp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021509976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534206A (ja
JP2021534206A5 (cg-RX-API-DMAC7.html
Inventor
リー ツァイ,
ミザール パテル,
イー リサ リュ,
Original Assignee
ラトガーズ、ザ ステイト ユニバーシティ オブ ニュージャージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラトガーズ、ザ ステイト ユニバーシティ オブ ニュージャージー filed Critical ラトガーズ、ザ ステイト ユニバーシティ オブ ニュージャージー
Publication of JP2021534206A publication Critical patent/JP2021534206A/ja
Publication of JP2021534206A5 publication Critical patent/JP2021534206A5/ja
Application granted granted Critical
Publication of JP7428404B2 publication Critical patent/JP7428404B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/30—Animals modified by surgical methods
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
JP2021509976A 2018-08-23 2019-08-16 Gsx1を使用した脊髄損傷(sci)および脳損傷の処置 Active JP7428404B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721679P 2018-08-23 2018-08-23
US62/721,679 2018-08-23
PCT/US2019/046881 WO2020041142A1 (en) 2018-08-23 2019-08-16 Treating spinal cord injury (sci) and brain injury using gsx1

Publications (3)

Publication Number Publication Date
JP2021534206A JP2021534206A (ja) 2021-12-09
JP2021534206A5 JP2021534206A5 (cg-RX-API-DMAC7.html) 2022-08-05
JP7428404B2 true JP7428404B2 (ja) 2024-02-06

Family

ID=69591287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509976A Active JP7428404B2 (ja) 2018-08-23 2019-08-16 Gsx1を使用した脊髄損傷(sci)および脳損傷の処置

Country Status (5)

Country Link
US (1) US20210268126A1 (cg-RX-API-DMAC7.html)
EP (1) EP3840729A4 (cg-RX-API-DMAC7.html)
JP (1) JP7428404B2 (cg-RX-API-DMAC7.html)
CA (1) CA3110309A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020041142A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230338529A1 (en) * 2020-08-06 2023-10-26 The Children's Medical Center Corporation Compositions for altering a microglial cell, and methods of use therefore
CN114231489A (zh) * 2020-09-08 2022-03-25 纽伦捷生物医药科技(苏州)有限公司 用于重编程的功能性片段、组合及其应用
CN112812167B (zh) * 2021-01-06 2023-04-11 东北师范大学 一种促进细胞存活的Netrin-1模拟肽、Netrin-1截短多肽及其应用
CN116879564A (zh) * 2023-09-06 2023-10-13 暨南大学附属第一医院(广州华侨医院) 基于蛋白质组学及磷酸化蛋白质修饰组学的脊髓损伤生物标志物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002250A1 (en) 2006-06-30 2008-01-03 Elena Kozlova Improved stem cells for transplantation and methods for production thereof
JP2013531988A (ja) 2010-06-14 2013-08-15 エフ.ホフマン−ラ ロシュ アーゲー 細胞透過性ペプチドおよびその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4206200A (en) * 1999-04-05 2000-10-23 Adherex Technologies Inc. Compounds and methods for stimulating beta-catenin mediated gene expression and differentiation
EP3246407B1 (en) * 2007-02-09 2019-04-03 Eisai R&D Management Co., Ltd. Gaba neuron progenitor cell marker 65b13
WO2010053522A2 (en) * 2008-10-29 2010-05-14 The Regents Of The University Of California Methods for identifying and producing neural stem and progenitor cells and their progeny
WO2010108126A2 (en) * 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Reprogramming compositions and methods of using the same
US20130189780A1 (en) * 2009-12-31 2013-07-25 Fate Therapeutics, Inc. Reprogramming compositions
CN103282487A (zh) * 2010-10-26 2013-09-04 卡斯西部储备大学 分化的体细胞向神经胶质细胞的细胞命运转化
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
WO2013155222A2 (en) * 2012-04-10 2013-10-17 The Regents Of The University Of California Brain-specific enhancers for cell-based therapy
WO2018106918A1 (en) * 2016-12-07 2018-06-14 The Children's Medical Center Corporation Neuronal survival and axonal regeneration through increasing mitochondrial motility

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002250A1 (en) 2006-06-30 2008-01-03 Elena Kozlova Improved stem cells for transplantation and methods for production thereof
JP2013531988A (ja) 2010-06-14 2013-08-15 エフ.ホフマン−ラ ロシュ アーゲー 細胞透過性ペプチドおよびその使用

Also Published As

Publication number Publication date
WO2020041142A1 (en) 2020-02-27
CA3110309A1 (en) 2020-02-27
JP2021534206A (ja) 2021-12-09
EP3840729A4 (en) 2022-05-18
US20210268126A1 (en) 2021-09-02
EP3840729A1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
JP6920324B2 (ja) 神経細胞の損失予防及び再生の効能を有するペプチド及びこれを含む組成物
CN108138150B (zh) 细胞透性改善的(iCP)帕金重组蛋白及其用途
US20210268126A1 (en) Treating spinal cord injury (sci) and brain injury using gsx1
JP7384672B2 (ja) C末端cdnf断片及びc末端manf断片、それらを含む医薬組成物、並びにそれらの使用
US20200071370A1 (en) Cell penetrating peptides that inhibit irf5 nuclear localization
KR20200005549A (ko) 신경퇴행성 장애 또는 뇌졸중의 치료에서 사용하기 위한 유전자 작제물
Liu et al. Intravenous PEP-1-GDNF is protective after focal cerebral ischemia in rats
JP2023521867A (ja) 改変インターロイキン22ポリペプチド及びその使用
CN111601815A (zh) 靶向细胞中c-Myc的嵌合分子
US20140288010A1 (en) Compositions and Methods for Increasing Stem Cell Survival
JP2025521778A (ja) 切断型タンパク質及びその使用
JP2013535965A5 (cg-RX-API-DMAC7.html)
JP2010503418A (ja) 細胞死受容体CD95による成体神経幹細胞の神経発生のinvivoおよびinvitroでの制御
EP3191186B1 (en) Compositions and methods of using interleukin-4 induced gene 1 (il4i1)
JP2023501308A (ja) 抗ミュラー管ホルモンポリペプチド
KR20200039621A (ko) 미엘린 장애의 치료를 위한 조성물 및 방법
US20220033450A1 (en) Virally expressed inhibitors of pdz domains, such as pick1 and uses thereof
CN101525602A (zh) 制备抗pink1多克隆抗血清的多肽及其应用
US11673916B2 (en) Neuroprotective peptides and methods of their use
US20250325709A1 (en) Gene delivery targeting neural stem cells and neural progenitor cells
KR20240095008A (ko) 신경염증성 질환 치료효과를 나타내는 신규 펩타이드 및 이의 용도
US9518104B2 (en) Compositions and methods for treating multiple sclerosis
US20230390359A1 (en) Use of reelin for treating cardiac diseases
WO2024021383A1 (zh) gp96及其在治疗肌萎缩侧索硬化的用途
WO2026105876A1 (ja) M1ミクログリア標的化融合ペプチド及びその利用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220728

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240118

R150 Certificate of patent or registration of utility model

Ref document number: 7428404

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150